Literature evidences have already demonstrated a) the presence of tumor transcripts in patients at stage I of melanoma [42], b) a wide in vitro variability in MITF-m levels depending on melanoma cell lines migration (low MITF-m expression cell lines have a migration rate twenty-three times higher than the high MITF-m expression ones) [43, 44], c) a reduction in vivo MITF levels in melanoma tumors of patients with high mortality rate compared to those observed in mild forms of CMM [45]. Here, MITF is linked to neoplasm.